March 2020 |
Differential effect of lacosamide on Nav1.7 variants from responsive and non-responsive patients with small fiber neuropathy |
Small fiber neuropathy |
Lacosamide |
I |
Yale University School of Medicine, New Haven, CT |
March 2020 |
Lack of detection of the analgesic properties of PF-05089771, a selective Na v 1.7 inhibitor, using a battery of pain models in healthy subjects |
Battery of human evoked pain models |
PF-05089771 alone and PF-05089771 concomitantly with pregabalin as treatment arms with pregabalin, ibuprofen, and placebo as control arms |
I |
Centre for Human Drug Research, Leiden, The Netherlands |
January 2020 |
Evaluation of the pharmacokinetic interaction between the voltage- and use-dependent Nav1.7 channel blocker vixotrigine and carbamazepine in healthy volunteers |
Peripheral neuropathic pain conditions, including trigeminal neuralgia |
Vixotrigine Carbamazepine |
I |
Biogen, Cambridge, Massachusetts, USA |
September 2019 |
Safety, tolerability, and pharmacokinetics of GDC-0276, a novel Na V 1.7 inhibitor, in a first-in-human, single- and multiple-dose study in healthy volunteers |
Pain relief |
GDC-0276 as powder-in-capsule (PIC) or cyclodextrin solution (CD) single doses |
I |
Genentech, Inc. |
February 2019 |
Lacosamide in patients with Nav1.7 mutations-related small fiber neuropathy: a randomized controlled trial |
Nav1.7 mutations-related small fiber neuropathy |
Lacosamide |
I |
Department of Neurology, School of Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands |
January 2019 |
Effects of a state- and use-dependent Nav1.7 channel blocker on ambulatory blood pressure: a randomized, controlled crossover study |
Neuropathic pain conditions |
Vixotrigine |
I |
Immunovant, Inc., Durham, NC, USA. |
December 2018 |
Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience |
Trigeminal neuralgia |
Vixotrigine |
IIa |
Facial Pain Unit, Division of Diagnostic, Surgical and Medical Sciences, Eastman Dental Hospital, University College London Hospitals NHS Foundation Trust/University College London, London, UK |
August 2018 |
Efficacy of the Nav1.7 blocker PF-05089771 in a randomized, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy. |
Diabetic peripheral neuropathy |
PF-05089771 |
I |
Pfizer WRD, Pain and Neuroscience Research Unit, Cambridge, UK |
April 2017 |
Safety and efficacy of a topical sodium channel inhibitor (TV-45070) in patients with postherpetic neuralgia (PHN): a randomized, controlled, proof-of-concept, crossover study, with a subgroup analysis of the Nav1.7 R1150W genotype |
Postherpetic meuralgia |
Topical sodium channel inhibitor (TV-45070) |
I |
Xenon Pharmaceuticals Inc. |
Apriil 2017 |
Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial |
Trigeminal neuralgia |
BIIB074 |
IIa |
Facial Pain Unit, Division of Diagnostic, Surgical and Medical Sciences, Eastman Dental Hospital, University College London Hospitals NHS Foundation Trust/University College London, London, UK |
July 2016 |
Clinical micro-dose studies to explore the human pharmacokinetics of four selective inhibitors of human Nav1.7 voltage-dependent sodium channels |
Chronic pain through inhibition of Nav1.7 channels |
Intravenous and oral PK of four compounds (PF-05089771, PF-05150122, PF-05186462 and PF-05241328) |
I |
Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide R&D, Sandwich, Kent, UK |
June 2016 |
Efficacy, safety, and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutation-related small fiber neuropathy: study protocol of a randomized controlled trial-The LENSS study |
Gain-of-function Nav1.7 mutation-related small fiber neuropathy |
Lacosamide |
I |
Department of Neurology, School of Mental Health and Neuroscience, Maastricht University Medical Center |
April 2016 |
Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia |
Inherited erythromelalgia |
PF-05089771 |
1 |
Pfizer Neuroscience and Pain Research Unit, The Portway Building, Granta Park, Cambridge CB21 6GS, UK. |
October 2011 |
Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker |
Inherited erythromelalgia |
XEN402 |
1 |
Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada |